A Mathematical Model of Thyroid Disease Response to Radiotherapy

  title={A Mathematical Model of Thyroid Disease Response to Radiotherapy},
  author={Araceli Gago-Arias and Sara Neira and Filippo Terragni and Juan Pardo-Montero},
We present a mechanistic biomathematical model of molecular radiotherapy of thyroid disease. The general model consists of a set of differential equations describing the dynamics of different populations of thyroid cells with varying degrees of damage caused by radiotherapy (undamaged cells, sub-lethally damaged cells, doomed cells, and dead cells), as well as the dynamics of thyroglobulin and antithyroglobulin autoantibodies, which are important surrogates of treatment response. The model is… 

Figures and Tables from this paper


Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine
A semi-mechanistic mathematical model describing tumor growth with the kinetics of thyroglobulin concentrations over time, following RAI for metastatic thyroid cancer is built, and classification criteria that could indicate whether patients will respond or not to RAI treatment are presented.
A kinetic model of continuous radiation damage to populations of cells: comparison to the LQ model and application to molecular radiotherapy.
This work presents a simple kinetic model that describes the kinetics of populations of tumor cells, rather than lethal/sub-lethal lesions, which may be especially useful for application to continuous dose rate therapies, as in molecular radiotherapy.
A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
A mathematical model to predict the final mass of Graves' diseased thyroids submitted to 131I therapy is presented and it is shown that the final thyroid mass depends on its basal mass, on the radiation dose absorbed by the gland and on a constant value alpha typical of thyroid tissue.
Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis
It is indicated that most DTC patients with pulmonary metastases can obtain partial or complete remission after RIT, while older patients with higher Tg levels at diagnosis and extrapulmonary distant metastases more likely show poor prognosis.
A patient-specific treatment model for Graves’ hyperthyroidism
The model can be used to predict when to discontinue the treatment based on FT4 levels within the physiological range, which in turn help maintain the remittance of euthyroidism and avoid relapses of hyperthyroidism.
Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy
RhTSH is adequately satisfactory as an adjuvant tool in therapeutic settings and is especially suitable in advanced recurrent or metastatic DTC patients who may be intolerant to TSH stimulation by levothyroxine withdrawal.
Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers
A differential equation model integrating thyroid hormone parameters, thyroid size, antibody titers and a complex algorithm encompassing genetic predisposition, environmental exposures and current immune activity is developed on the basis of published clinical trials in patients with Graves’ disease.
Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.
Evaluated responses to therapeutic irradiation with 131I in 76 patients with thyroid adenocarcinoma found patients with metastases that persisted after 131I therapy tended to have more advanced disease and received significantly lower radiation doses per millicurie of administered 131I than did persons whose lesions responded to treatment.
A dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction.
The meaning of the fixed value of target absorbed dose (Gy) is discussed and a mathematical model for remnant/metastasis optimum absorbed dose calculation is presented, based on the desired reduction of the volume of the target (remnant or metastasis).
Dosimetry and thyroid cancer: the individual dosage of radioiodine.
Treatment of children and adolescents with radioiodine requires special precautions; individualized approaches in this setting are reviewed and new concepts for further elaborating the potential of thyroid cancer treatment using (131)I are introduced.